I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

AbbVie-partnered Mission Therapeutics is tweaking its trajectory, closing a preclinical laboratory in the U.K. to focus on ...

AbbVie, Danaher, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock ...

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra. AbbVie said it will pay up to about $2.2 billion for the drug GUBamy, which is currently in a Phase 1 ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie (NYSE:ABBV) in the last three months. The table below provides a concise overview of ...

Once a division of the medical device giant Abbott Laboratories, AbbVie has been a stand-alone publicly traded company since 2013. In that time, the drugmaker produced market-beating returns and ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six ...